MiR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8⁺ T cell infiltration.

ABSTRACT: Immunotherapies have emerged as promising strategies for cancer treatment. However, existing immunotherapies have poor activity in high-grade serous ovarian cancer (HGSC) due to the immunosuppressive tumor microenvironment and the associated low tumoral CD8⁺ T cell (CTL) infiltration. Through multiple lines of evidence, including integrative analyses of human HGSC tumors, we have identified miR-146a as a master regulator of CTL infiltration in HGSC. Tumoral miR-146a expression is positively correlated with anti-cancer immune signatures in human HGSC tumors, and delivery of miR-146a to tumors resulted in significant reduction in tumor growth in both ID8-p53^-/- and IG10 murine HGSC models. Increasing miR-146a expression in tumors improved anti-tumor immune responses by

SUBMITTER: Chen R 

PROVIDER: S-EPMC10539880 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature